Nasopharyngeal carcinoma, susceptibility to, 1
MONDO:0011775Any nasopharyngeal carcinoma in which the cause of the disease is a mutation in the TP53 gene.
Also known as: TP53 nasopharyngeal carcinoma, nasopharyngeal carcinoma 1, nasopharyngeal carcinoma caused by mutation in TP53, nasopharyngeal carcinoma, somatic, nasopharyngeal carcinoma, susceptibility to, 1, NPC, Npca, nasopharyngeal cancer
55 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Experimental cancer drug TAK-500 tested in 61 patients – study halted early
Disease control TerminatedThis early-phase trial tested an experimental drug called TAK-500, alone or with the immunotherapy pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The stud…
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental cancer drug INCB062079 tested in early trial
Disease control TerminatedThis early-phase trial tested a new drug called INCB062079 in 25 people with advanced liver cancer and other solid tumors. The main goal was to check safety and find the best dose. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC